GLP-1 Medications Reconsidered, Cyborg Cockroach Rescue Robots, and a Universal Flu Drug Alternative

Broadcast from KSQD, Santa Cruz on 7-02-2026:

Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins.

Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 .

Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible.

Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication.

A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center.